Aligos Therapeutics Inc (ALGS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aligos Therapeutics Inc (ALGS) has a cash flow conversion efficiency ratio of -0.406x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.75 Million) by net assets ($53.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aligos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Aligos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Aligos Therapeutics Inc (ALGS) total liabilities for a breakdown of total debt and financial obligations.
Aligos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aligos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NextCure Inc
NASDAQ:NXTC
|
-0.265x |
|
NXT Energy Solutions Inc
TO:SFD
|
-0.086x |
|
KCP Sugar and Industries Corporation Limited
NSE:KCPSUGIND
|
0.087x |
|
Tong-Hwa Synthetic Fiber Co Ltd
TW:1418
|
-0.051x |
|
Seoyon Topmetal Co. Ltd
KQ:019770
|
-0.023x |
|
Biotoxtech Co. Ltd
KQ:086040
|
-0.010x |
|
OnKure Therapeutics, Inc.
NASDAQ:OKUR
|
-0.196x |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
0.097x |
Annual Cash Flow Conversion Efficiency for Aligos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Aligos Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ALGS market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $53.55 Million | $-82.50 Million | -1.541x | -155.29% |
| 2024-12-31 | $-28.97 Million | $-80.74 Million | 2.787x | +424.84% |
| 2023-12-31 | $92.08 Million | $-79.00 Million | -0.858x | -12.28% |
| 2022-12-31 | $103.90 Million | $-79.39 Million | -0.764x | -22.04% |
| 2021-12-31 | $184.73 Million | $-115.66 Million | -0.626x | -85.51% |
| 2020-12-31 | $220.04 Million | $-74.26 Million | -0.337x | -146.83% |
| 2019-12-31 | $-64.89 Million | $-46.77 Million | 0.721x | +63.80% |
| 2018-12-31 | $-13.75 Million | $-6.05 Million | 0.440x | -- |
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifosc… Read more